Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion

The RAS-RAF-MEK-ERK pathway is deregulated in over 90% of malignant melanomas and targeting MEK as central kinase of this pathway is currently tested in clinical trials. However, dose-limiting side effects are observed, and MEK inhibitors that sufficiently reduce ERK activation in patients show a lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Jennifer, Arozarena, Imanol, Ehrhardt, Michael, Wellbrock, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378628/
https://www.ncbi.nlm.nih.gov/pubmed/22310287
http://dx.doi.org/10.1038/onc.2012.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378628/
https://www.ncbi.nlm.nih.gov/pubmed/22310287
http://dx.doi.org/10.1038/onc.2012.25

Ejemplares similares